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Abstract—Trypanothione reductase (TryR) is a well-established target in the search for novel 
antitrypanosomal and antileishmanial agents. We have previously identified linear and lactam-
bridged 13-residue peptides derived from an -helical region making up part of the dimeric 
interface of Leishmania infantum TryR (Li-TryR) which prevent trypanothione reduction by 
disrupting enzyme dimerization. We now show that i,i+4 side-chain cross-linking with an all-
hydrocarbon staple stabilizes the helical structure of these peptides and significantly improves 
their resistance to protease cleavage relative to previous linear and cyclic lactam analogues. 
Interestingly, replacement of the amide bridge by the hydrocarbon staple at the same 
cyclization positions generates derivatives (2 and 3) that similarly inhibit oxidoreductase 
activity of the enzyme but unexpectedly stabilize the TryR homodimer. The most 
proteolytically stable peptide 2 covalently linked to oligoarginines displayed potent in vitro 
leishmanicidal activity against L. infantum parasites. 
 
Keywords- stapled peptides, protein-protein interactions, trypanothione reductase, Leishmania 
infantum, cell-penetrating peptides.  
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Highlights 
 
 
 All-hydrocarbon stapled peptides were derived from the monomer-monomer interface 
of Li-TryR  
 
 Li-TryR oxidoreductase activity was potently inhibited by these peptides 
 
 Unexpected stabilization of the TryR homodimer was observed 
 
 -helicity and proteolytic stability were significantly increased relative to their linear 
counterparts 
 
 Conjugation with cell-penetrating peptides resulted in leishmanicidal activity 
 
 
  
Introduction 
Leishmania parasites are the causative agents of leishmaniasis, a neglected tropical disease that 
is still endemic in more than 80 countries worldwide, according to the World Health 
Organization. The most lethal form of the disease is visceral leishmaniasis (VL), also known as 
kala-azar, predominantly caused by Leishmania donovani and Leishmania infantum species 
which is invariably fatal if left untreated [1]. Because resistance to current therapeutic options, 
which involve long and costly treatments, is commonplace and the medicines used are 
considerably toxic [2-4], there is a pressing need for innovative drugs that act on new molecular 
targets and/or employ novel mechanisms of action. 
A frequently exploited strategy to develop potent and specific antileishmanial drugs is to try 
and disrupt a metabolic pathway that is vital for the parasite and has no direct counterpart in the 
host. Trypanothione reductase (TryR), due to its key role in the maintenance of cellular redox 
homeostasis in Leishmania and other trypanosomatids, is an essential enzyme for survival of 
these parasites [5,6]. The Try/TryR system is analogous to the mammalian 
glutathione/glutathione reductase (GSH/GR) pair involved in redox status regulation. However, 
the significant differences in the active site architectures of the enzymes from parasites and 
human beings facilitate the development of inhibitors selective for TryR over H-GR. TryR is a 
well-established drug target for antiparasitic drug design, with almost all known inhibitors 
targeting its active site [7-9].
 
This enzyme belongs to the large and well-characterized family of 
FAD-dependent NADPH oxidoreductases. From a structural viewpoint, TryR is a homodimer 
containing distinct domains for FAD-binding, NADPH-binding and interfacial recognition.  
We recently explored an alternative approach for TryR inhibition that consists of disrupting 
protein-protein interactions (PPIs) at the homodimer interface [10]. Computational and 
experimental site-directed mutagenesis studies identified and validated E436 as a key amino 
acid (“hot spot”) for the structural stability and function of the Leishmania infantum TryR (Li-
TryR) homodimer. The "proof of concept" was obtained when a small library of linear peptides 
representing rational variations of the α-helix spanning residues P435 to M447 was designed 
and tested. All of these peptides contained a Glu residue at position 2 (Glu
2
) equivalent to the 
crucial E436 of Li-TryR. Unexpectedly, the linear PKIIQSVGIS-Nle-K-Nle 13-residue peptide 
1, containing Lys
2
 in place of Glu
2
, outperformed all other peptides in inhibiting both Li-TryR 
dimerization and oxidoreductase activity [10]. A rationale for these findings was provided by 
results from molecular dynamics (MD) simulations, which showed Lys
2
 of the peptide can 
establish a strong electrostatic interaction with both D432 and E436 in the Li-TryR monomer it 
putatively binds to. Nonetheless, these peptide prototypes, despite their potency in inhibiting 
TryR dimerization and enzymatic activity in vitro, were ineffective against L. infantum axenic 
amastigotes and promastigotes, most likely due to their inability to cross the cell membrane, as 
assessed by using FITC-labeled peptides [10]. 
Short peptide sequences normally have negligible or random structure in water, whereas 
their binding targets usually recognize a specific conformation. The biological activity of 
peptide analogs can be improved by stabilizing their secondary structure and limiting their 
proteolysis through covalent cyclization [11-13], most often by means of side chain-to-side 
chain linkage. In stabilizing -helices, the use of lactam bridges [14-16] and, more recently, 
short hydrocarbon chains [17-19] as staples has proven to be a successful approach to enhance 
helicity and to limit degradation by proteases of the resulting stapled peptides. In the case of 
hydrocarbon linkages, improvements in oral absorption
 
[20] and cell permeability [21-23] have 
also been reported although these are two of the most significant yet poorly understood aspects 
of peptide stapling technology [24,25].
 
So far, numerous examples of conformationally 
restricted peptides for several therapeutic targets have been reported to succesfully modulate 
PPIs [26-28].
 
We recently reported [29]
 
an example
 
of helical content stabilization by preparing and 
testing a series of cyclic analogues of the most potent linear prototype TryR inhibitor 1 that 
were amide-bridged between amino acid side chains i and i+4. Our results indicated that 
several cyclic analogues retained potent inhibitory activity against the enzyme (when the staple 
was properly located) but also that their proteolytic stability against proteinase K was only 
modestly increased in comparison to those of their linear counterparts. Interestingly,
 
we later 
demonstrated, for the first time to the best of our knowledge, in vitro activity against 
Leishmania infantum of peptide-based inhibitors of TryR dimerization when they were 
conjugated to cationic cell-penetrating peptides (CPPs) [29].
 
We herein report the synthesis of all-hydrocarbon stapled peptides 2 and 3 (Figure 1), 
derived from the most potent linear prototype 1, which were designed as inhibitors of Li-TryR 
dimerization and activity with improved proteolytic stability over those of previous linear and 
lactam-bridged peptides. Their potential to penetrate cells and exert their leishmanicidal 
effects was also evaluated in vitro. Hydrocarbon cross-links were introduced between amino 
acid side-chains that are separated by one helical turn (i, i+4). The location of the 
hydrocarbon bridge at the non-recognition side was chosen on the basis of results obtained for 
the first series of lactam-bridged analogues, for which the best activities were found upon 
cyclization between positions 3/7 and 4/8 of the peptide sequence. Other possible cyclization 
positions resulted in a significant potency loss [29]. Thus, in line with these precedents, 
stapling positions 3/7 and 4/8, leading to hydrocarbon-stapled peptides 2 and 3, respectively, 
were selected. Fluorescein–labeled peptide conjugate 4 and the most proteolytically stable 
hydrocarbon-stapled peptide conjugated to a polyarginine CPP (5) (Figure 1) were also 
prepared for cellular uptake studies using fluorescence microscopy and in vitro evaluation of 
their antileishmanial activity.  
 Figure 1. Structures of the linear prototype 1 and the designed all-hydrocarbon stapled 
compounds 2-5 synthesized in this work. 
 
 
Results and Discussion 
Chemical synthesis  
The synthesis of the all-hydrocarbon stapled peptides was performed manually following 
standard solid-phase peptide synthesis (SPPS) protocols using a Rink amide MBHA 
polystyrene resin and N-Fmoc/
t
Bu chemistry. The peptides were isolated acetylated at the N-
terminus and as carboxamides at the C-terminal end. A low load resin (0.38 mmol/g) was 
used to minimize oligomer formation during the side-chain to side-chain cyclization.  
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The preparation of hydrocarbon-stapled peptides 2 and 3 was carried out by introduction of 
two units of Fmoc-(S)--methyl--pentenylglycine at the suitable positions of the sequence in 
the elongation step as previously described by Verdine and co-workers (Scheme 1) [30,31]. 
Linear precursors 8 and 9 were prepared from the corresponding solid-supported linear 
peptides 6 and 7 after Fmoc-deprotection, acetylation and final cleavage from the resin. 
Dicarba bridge formation was accomplished through on-resin ring-closing metathesis (RCM) 
using Grubb’s second-generation ruthenium catalyst. Initial efforts to perform RCM at room 
temperature or prolonged heating at 90 °C for 12 h in a pressure tube using CH2Cl2 as the 
solvent resulted in little to no conversion to the stapled peptide. However, when the mixture 
was heated under MW irradiation at 75 °C for 1 h, complete conversion was detected by 
HPLC-MS after cleavage of a small quantity of peptidyl-resin [32]. Next, the N-terminus of 
the peptides was acetylated, cleaved from the resin under standard conditions and purified by 
semi-preparative HPLC. Both E and Z isomers of 2 and 3 were detected by HPLC, which 
allowed the separation, isolation and subsequent biological evaluation of 2a and 2b. In the 
case of stapled peptide 3a only the major isomer could be isolated. E and Z isomers are 
generally distinguished by the value of the 
3
JHH coupling constant between the vinyl protons 
(Hε and Hε’ in the case of peptides 2a,b and 3a). This 3JHH constant could not be measured in 
either isomer 2a or 2b because both isomers have similar
 1H chemical shifts for Hε and Hε’ 
protons (5.47 ppm in major isomer 2a, and 5.36 ppm in minor isomer 2b; Tables S1-S2). In 
the case of the major isomer of 3, the 
1H chemical shifts for the protons Hε and Hε’ are 
distinguishable, and the 
3
JHH coupling constant between them is approximately 18.6-19.0 Hz, 
which indicates that, most likely, it corresponds to the E isomer.  
 Scheme 1.  Synthesis of all-hydrocarbon stapled peptides 2 and 3 and the linear precursors 8 and 9.  
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Fluorescein–labeling of the most proteolytically stable 2a was achieved by linking the N-
terminal group to FITC through a PEG linker (to increase aqueous solubility). To this end, 
standard sequences of Fmoc-deprotection and coupling with Fmoc-PEG-OH and FITC-NCS 
followed by TFA cleavage from the resin gave the desired compound 4 (Scheme 2).  
Finally, to deliver the peptides into the parasites for leishmanicidal in vitro evaluation, the 
N-terminal end of 2a was covalently linked to a polyarginine (R9) chain using standard SPPS 
methodology (compound 5, Scheme 2), as previously reported for our CPP-conjugates of 
linear peptide prototypes, lactam-bridged analogues and ,-peptide foldamers [10,29,33]. 
All hydrocarbon-stapled peptides and linear precursors in this work were characterized by 
analytical HPLC and ESI-MS or MALDI-TOF after purification on a Biotage Isolera (linear 
analogues) or by semi-preparative HPLC (cyclic analogues) leading to the linear and cyclic 
peptides in low/moderate yields and high purity (>95%).  
  
  
Scheme 2.  Synthesis of the major isomers of fluorescently labeled hydrocarbon-stapled 
peptide 4 and polyarginine-stapled conjugate 5. 
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CD studies and proteolytic stability 
We used circular dichroism (CD) to determine the effect of the olefinic cross-link on the 
helical propensity of the peptides. The CD spectra were acquired in water in the presence of 
the secondary structure-promoting solvent 2,2,2-trifluoroethanol (TFE) (30% TFE/water) 
[34,35]. TFE was selected as cosolvent due to the poor solubility of the linear hydrophobic 
peptide 1 in water. As expected, 2a and 3a showed the dual minima at 222 nm and 208 nm 
typical of -helices in contrast to the linear prototype 1, which exhibited a CD spectrum 
characteristic of an unstructured peptide (Figure 2). The percentage of -helicity calculated 
for 2a and 3a, as calculated from the molar elipticity value at 222 nm and the number of 
amino acids using the equation of Baldwin and col. [36], is 64 and 43%, respectively. Similar 
enhancements of helicity have been reported previously in related lactam-bridged peptide 
analogues [29]. 
 
   
 
Figure 2. CD spectra and experimentally determined helicities (%) of hydrocarbon-stapled 
peptides 2a and 3a and linear peptide 1.  
We next compared the susceptibilities to degradation by proteinase K, a serine protease with 
broad substrate specificity, of the linear prototype 1 and the major isomers of hydrocarbon-
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stapled peptides 2a and 3a. The half-life of both 2a and 3a significantly increased (up to 18-
fold) compared to those of 1 (t1/2 values of 418 and 212 min vs 23 min) and the previously 
described lactam-bridged analogues (t1/2 values of 52 and 64 min) [29]. 
 
Biological activity 
Enzymatic assays 
The effect of 2a and 3a and their linear precursors 8 and 9 on the activity and dimeric status 
of Li-TryR was evaluated (Table 1). Our results demonstrate that stapling modestly decreases 
the potency of the compounds as Li-TryR inhibitors relative to the linear peptide 1 and the 
corresponding 3,7- or 4,8- lactam-bridged analogues (Table 1). In stark contrast, their activity 
as disruptors of Li-TryR dimerization is completely abolished and, surprisingly, some of them 
(analogues 2a, 3a and 9) even behave as stabilizers of the dimeric form of the enzyme, as 
demonstrated by the increased ELISA signal derived from the Li-TryR dimer after incubation 
with these compounds (Figure S4). This stabilizing effect had not been previously observed 
and might be indicative of an unexpected interaction of the stapled peptides with Li-TryR that 
somehow impairs dimer disruption. 
A deleterious effect on the disruptive activity of the peptides upon stapling was previously 
observed for analogues containing a Glu residue at position 2 (Glu
2
) [32]. Thus, the present 
study reinforces our previous observations about the important nature of the covalent linker 
(lactam vs hydrocarbon) for TryR dimer destabilization and is in line with observations by 
others suggesting that the increase in overall hydrophobicity of the stapled peptide likely 
impacts not only the protein structure but also the interdomain water dynamics [37] because 
the water molecules present at the interface between protomers are likely to behave very 
differently depending on the polarity of the linker. The intriguing paradox is that inhibition of 
TryR activity appears to arise from either stabilization or destabilization of the homodimer. In 
both cases, the protein motions that presumably occur during the catalytic cycle are likely to 
be prevented or hampered due to binding of the peptide to one of the monomers. It is 
conceivable that the ensuing decrease in reduced trypanothione formation leads to the 
observed growth inhibition.  
 
Table 1. Potency of hydrocarbon-stapled peptides 2 and 3 and linear precursors 8 and 9 in the 
Li-TryR oxidoreductase activity and dimerization assays. 
Peptide Activity assay 
IC50 (M)
a
 
Dimerization assay 
IC50 (M) 
1 (linear prototype)  1.2 ± 0.2 13.5 ± 2.4 
3,7-lactam-bridged analogue
c
  0.9 ± 0.1 9.9 ± 1.6
b
 
4,8-lactam-bridged analogue
c
  5.3 ± 0.8 14.4 ± 1.8
b
 
2a (3,7-hydrocarbon-stapled, major isomer)  6.7 ± 0.4 Homodimer 
stabilizer 
2b (3,7-hydrocarbon-stapled, minor isomer)  >25 No effect 
3a (4,8-hydrocarbon-stapled, major isomer) 6.4 ± 0.6 Homodimer 
stabilizer 
8 (linear precursor 2)  28.2 ± 1.7 No effect 
9 (linear precursor 3)  12.5 ± 1.1 Homodimer 
stabilizer 
a 
>25 indicates that the IC50 is higher than 25 M (maximum concentration assayed). Results are 
representative of three independent experiments each performed in triplicate. 
b 
Data from lactam-
bridged analogues [29] are included for comparative purposes. 
 
Because of the functional and structural similarities between Li-TryR and human GR (H-GR), 
we compared the activity of peptides 2a and 3a against both enzymes under similar conditions. 
Surprisingly, both Li-TryR inhibitors activate, rather than inhibit, H-GR’s oxidoreductase 
activity (Figure 3).  
 
 Figure 3. Oxidoreductase activity of Li-TryR and H-GR measured as the increase in 
absorbance at 412 nm (reduction of DTNB coupled to T[SH]2 or GSH production, 
respectively). Activity of the enzymes in the presence of either 1.75% DMSO (♦), 75 µM 2a 
(■) or 75 µM 3a (▲). 
 
In vitro antileishmanial activity 
The all-hydrocarbon stapled analogues 2a and 3a and the linear precursors 8 and 9 were tested 
in vitro against L. infantum promastigotes and axenic amastigotes to evaluate their 
antileishmanial activity.  Edelfosine and miltefosine were included in the assays as positive 
controls. None of the compounds displayed any activity at 25 M (maximum concentration 
assayed). Fluorescence microscopy with the fluorescein–labeled conjugate [Flu]-PEG-
[peptide] (compound 4) demonstrated the low ability of the hydrocarbon-bridged analogues to 
cross the cell membrane (data not shown). To deliver the peptides into the parasites, 2 was 
covalently linked to an R9 sequence used as a CPP (compound 5), following the successful 
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strategy already employed for the efficient uptake of the linear peptide prototype 1 and 
several lactam-bridged and mixed ,-peptide foldamer analogues [29,33]. The R9 sequence 
was also studied in parallel as a control. The EC50 values obtained demonstrate that the 
leishmanicidal activity of 5 against axenic amastigotes and promastigotes is similar to that 
observed for the reference drugs edelfosine and miltefosine, as well as for the previously 
obtained linear and lactam cyclic peptide analogues. 
 
Table 4.  EC50 ± SEM values for the [R9]-[stapled peptide] conjugate 5 on L. infantum 
promatigotes, amastigotes and cytotoxic activity in the THP-1 cell line.
a
 
 Compound
b
 EC50 (M) 
Promastigotes 
EC50 (M) 
Amastigotes 
EC50 (M) 
THP-1 
5 
RRRRRRRRRPKPK-
c[(CH2)3CH=CH(CH2)3]
3,7
[A*IQSA*]GISNLKNL  
1.95 ± 0.14 
 
2.14 ± 0.5 0.33 ± 0.05 
11 
RRRRRRRRR
c
 
> 25 > 25 > 25 
12 
RRRRRRRRR 
PKIIQSVGISNLKNL
c
 
4.6 ± 0.2 3.5 ± 0.9 1.7 ± 0.5 
13 
RRRRRRRRRPK-
c[(CH2)2CONH(CH2)4]
3,7 
[EIQSK]GISNLKNL
c
 
3.5 ± 0.4 2.8 ± 0.3 2.5 ± 0.8 
Edelfosine 9 ± 0.2 0.6 ± 0.1 1 ± 0.2 
Miltefosine 47.6 ± 0.6 2 ± 0.1 19 ± 1.6 
a
Results are representative of three independent experiments each performed in 
triplicate. 
b
All the peptides are acetylated at the N-terminus and contain a carboxamide 
C-terminal group. 
c
Data from R9 conjugates of linear peptide 1 (compound 12), the 
corresponding amide-bridged peptide conjugate 13 and the R9 sequence 11 are taken 
from reference [29] for comparative purposes. 
 
 
Conclusions 
A series of all-hydrocarbon stapled peptides was designed with the aims of improving the 
proteolytic stability, enhancing the enzyme inhibition activity and increasing the cell 
permeability of previously reported linear peptide and lactam-bridged analogues that target 
the dimerization interface of Li-TryR. Although the new stapled peptides retain potent 
inhibitory activity against Li-TryR and are shown to be more resistant to proteolysis, they lose 
their ability to act as Li-TryR disruptors and appear to act as dimer stabilizers. The structural 
aspects involved in this unexpected and remarkable reversal in the mode of action await 
further elucidation. Attempts to co-crystallize Li-TryR with these stapled peptides for X-ray 
diffraction studies is currently underway as previous attempts of co-crystallization with linear 
or lactam-bridged analogues were hampered by the finding that the monomeric form of Li-
TryR precipitates.  
The stapled peptides are not able to cross the cell membrane, as assessed by fluorescence 
experiments using an FITC-labeled peptide. Nonetheless, conjugation of the most 
proteolitically stable hydrocarbon-stapled peptide 2 to an R9 CPP favors intracellular uptake 
and turns this compound into a molecule highly active against both promastigotic and axenic 
amastigotic forms of cultured L. infantum parasites. Therefore, we conclude that all-
hydrocarbon stapling of linear TryR dimerization peptide inhibitors does not significantly 
enhance cell permeability over that of alternatively cross-linked derivatives but has a major 
impact on their proteolytic stability as well as on their mode of interaction with the TryR 
homodimer.  
 
  
EXPERIMENTAL 
1. Chemistry 
1.1. General Methods 
Unless otherwise noted, analytical grade solvents and commercially available reagents were 
used without further purification. DIEA, piperidine, Ac2O and EDT were purchased from 
Aldrich (Germany), TFA from Fluka (Germany) and HCTU from Fluorochem (UK). Fmoc-
protected amino acids were purchased from Fluorochem (UK), Polypeptide (France), 
Novabiochem (Merck, Germany) and Iris Biotech (Germany). Fmoc-protected Rink Amide 
MBHA resin (0.56 mmol/g and 0.38 mmol/g loading) was purchased from Iris Biotech 
(Germany) and Novabiochem. All-hydrocarbon stapled peptides 2-5 and linear precursors 8 and 
9 were synthesized manually on a 20-position cartridge manifold (Omega) in a 20-mL 
polypropylene syringe (Dulbecco) equipped with a porous polyethylene filter. The coupling 
reactions were carried out on solid phase using microwave radiation in a Biotage Initiator 
reactor in a 5 mL vial. Excluding the coupling reaction on the microwave reactor, the rest of the 
SPPS reactions were stirred using an IKA-100 orbital shaker. 
After cleavage, the acidic crudes were sedimented in Et2O on a Hettich Universal 320R 
centrifuge at 5000 rpm. All the crude and samples were lyophilized using mixtures 
water/acetonitrile on a Telstar 6-80 instrument. The monitoring of the reactions was also 
performed by HPLC/MS through a HPLC-waters 12695 connected to a Waters Micromass ZQ 
spectrometer. The linear peptides were purified on a Biotage Isolera instrument using reverse 
phase columns (KP-C18-HS 12 g) and the cyclic peptides were purified on a semipreparative 
HPLC instrument. As the mobile phase, mixtures of A:B were used, where A = 0.05% TFA 
water and B = acetonitrile with a flow rate of 7 mL/min. The peptides were purified using a 
gradient from 0% of B to 100% of B in 30-45 min and were detected at 217 nm. 
 
NMR spectra of cyclic peptides 2a, 2b and 3a were acquired using a Bruker AV-600 
spectrometer, equipped with a cryoprobe, running at 600.13 MHz for 
1
H. The TOPSPIN 
software (Bruker Biospin, Karlsruhe, Germany) was used for spectral processing. 
1
H-chemical 
shifts (δ), reported in ppm relative to the internal reference sodium 2,2-dimethyl-2-
silanpentane-5-sulfonate (DSS), were assigned by the standard sequential method [38], based 
on the analysis of 2D Homonuclear spectra (
1
H,
1
H-COSY, 
1
H,
1
H-TOCSY, 
1
H,
1
H-NOESY). 
Once assigned the 
1
H resonances, 2D 
1
H,
13
C-HSQC spectra recorded at natural 
13
C abundance, 
were analysed to determine the 
13
C chemical shifts, which were referenced using the IUPAC 
recommended 
1
H/
13
C ratio (0.25144953 [39]). All the NMR spectra were analysed using the 
SPARKY software (T.D. Goddard and D. G. Kneller, University of California, USA). 
The purity of the peptides was checked by analytical RP-HPLC on an Agilent Infinity 
instrument equipped with a Diode Array and a C18 Sunfire column (4.6 mm x 150 mm, 3.5 
μm). As mobile phase, A:B mixtures were used, where A = 0.05% TFA water and B = 
acetonitrile. The samples were analyzed at 214 and 254 nm in a gradient from 2% of B to 100% 
of B in 15 min (gradient 1). HRMS (EI+) was carried out in an Agilent 6520 Accurate-Mass Q-
TOF LC/MS spectrometer using water/acetonitrile mixtures. MALDI-TOF mass spectrometer 
(Voyager DE-STR Applied Biosystems) operated in reflectron mode to obtain better resolution 
was used for the [R9]-[hydrocarbon-stapled peptide] conjugate 5. 
 
1.2. Solid-Phase Peptide Synthesis (SPPS) 
Peptides were synthesized manually on resin following the standard Fmoc/tBu solid-phase 
orthogonal protection strategy. 
General coupling procedure. Fmoc-protected Rink Amide MBHA resin was swollen in 
DCM/DMF/DCM/DMF (4 x 0.5 min). Then, the resin was treated with a mixture of 
DBU:piperidine:DMF (1:1:48, in volume) at room temperature (1 x 1 min) and (3 x 10 min) 
and washed with DMF/DCM/DMF/DCM (4 x 0.5 min). Later, to the free Nα-terminal swollen 
resin (1 equiv.), a solution of the corresponding Fmoc-AA-OH (1.2 equiv.), HCTU (1.2 equiv.) 
and DIEA (2.4 equiv.) in dry DMF (5 mL) was added. After sealing the vial, the reaction was 
heated in a microwave vial equipped with a magnetic stirrer for 10 minutes at 40 ºC. Then, the 
vial was opened, the supernatant removed and new coupling mixture added. This process was 
repeated 3 times in total (3 x 10 min) until complete coupling. Finally, the resin was transferred 
to a fritted syringe, drained and washed extensively (DMF/DCM/DMF/DCM, 5 x 0.5 min). 
This protocol was repeated for the sequential anchoring of each amino acid. Coupling reactions 
to primary amines were monitored by the Kaiser ninhydrin test and to secondary amines by the 
Choranil test. In some cases, the progress of the reactions was also followed by analysis of a 
small sample of peptidylresin after acidic cleavage in an HPLC-MS instrument. 
General acetylation procedure. After elongation of the peptides, the N-terminal group was 
acetylated in all the cases by DBU deprotection of the Fmoc-resin-bounded derivative as 
mentioned above followed by treatment of the deprotected resin with a mixture of 
Ac2O:DIEA:DMF (1:1:1, in volume) at room temperature (1 x 1 min) and (4 x 10 min). The 
resin was finally washed with DMF/DCM/DMF/DCM (4 x 0.5 min). 
Ring closing metathesis (RCM) reaction. To the peptidylresins swollen in anhydrous CH2Cl2 
(5 mL) in a microwave vial (5–10 mL) second generation Grubb's catalyst (0.2 equiv.) was 
added and the vial was sealed and gently bubbled with argon. Then, the reaction was heated at 
75 ºC using microwave radiation for 1 h. The resin was then filtered and washed successively 
with CH2Cl2/MeOH. Residual ruthenium impurities were removed by stirring the resin bound 
peptide with a solution of DMSO (50 equiv. relative to the catalyst) in DMF for 12 h. Finally, 
the resin was washed with DMF/CH2Cl2/MeOH (3 x 0.5 min). 
General cleavage procedure. The well dried resin-bound derivative (1 volume) in a fritted 
syringe was treated with TFA:TIPS:H2O 95:2.5:2.5 (5 volumes) for 4 h at room temperature. 
The filtrates were precipitated over cold Et2O and centrifuged three times at 5000 rpm for 10 
min. After removing the supernatant, the pellet was redissolved in water/acetonitrile and 
lyophilized. The crudes were purified to give the target peptides 2-5 in high purity. 
 
Ac-PK-c[(CH2)3CH=CH(CH2)3]
3,7
[A
*
IQSA
*
]GISNLKNL-NH2 (2a,b). After elongation of the 
peptide starting from 0.03 mmol of Rink amide resin, the metathesis reaction was carried out 
for 1 h following the general protocol under microwave conditions. Then, the cyclic peptide 
was N-acetylated and cleaved from the resin. The crude was purified by reverse phase 
chromatography using semipreparative HPLC to give the cyclic peptide 2a as major isomer 
(11.36 mg, 4% overall yield) and 2b as minor isomer (3.51 mg, 1% overall yield).  
Major isomer 2a: HPLC (gradient 1): 7.47 min (96% analytical purity). HRMS (ESI,+) m/z: 
calculated for C70H123N17O17 1473.9283; found 1473.9262 (-1.41 ppm).
 1
H-NMR (600 MHz, 
D2O : H2O, 1 : 9) and 
13
C-NMR (150 MHz, D2O : H2O, 1 : 9) in Table S1. 
Minor isomer 2b: HPLC (gradient 1): 6.90 min (96% analytical purity). HRMS (ESI,+) m/z: 
calculated for C70H123N17O17 1473.9283; found 1473.9302 (1.32 ppm). 
1
H-NMR (600 MHz, 
D2O : H2O, 1 : 9) and 
13
C-NMR (150 MHz, D2O : H2O, 1 : 9) in Table S2. 
 
Ac-PKI-c[(CH2)3CH=CH(CH2)3]
4,8
[A
*
QSVA
*
]ISNLKNL-NH2 (3a). After elongation of the 
peptide starting from 0.33 mmol of Rink amide resin, the metathesis reaction was carried out 
for 60 min following the general protocol under microwave conditions. After N-acetylation and 
cleavage from the resin, the crude was purified by semipreparative HPLC to yield the major 
isomer (E) of cyclic derivative 3a (10 mg, 2% overall yield) as a white solid. 
Major isomer 3a: HPLC (gradient 1): 8.68 min (96% analytical purity). HRMS (ESI,+) m/z: 
calculated for C73H129N17O17 1515.9752; found 1515.9722 (-1.99 ppm).
 1
H-NMR (600 MHz, 
D2O : H2O, 1 : 9) and 
13
C-NMR (150 MHz, D2O : H2O, 1 : 9) in Table S3. 
 Ac-FITC-PEG-PK-c[(CH2)3CH=CH(CH2)3]
3,7
[A
*
IQSA
*
]GISNLKNL-NH2 (4). After 
elongation of the peptide starting from 0.152 mmol of Rink amide resin (0.38 mmol/g), the 
metathesis reaction was carried out for 1 h following the general protocol under microwave 
conditions. Then, the Fmoc group was removed and the resin was treated with {2-[2-(Fmoc-
amino)ethoxy]ethoxy}acetic acid (2 equiv.), HCTU (2 equiv.) as coupling reagent and DIEA (4 
equiv.) for 2 h at room temperature. Fmoc group was removed and resin was treated with 
fluorescein isothiocyanate (FITC) (2 equiv.) and DIEA (3 equiv.) at room temperature 
overnight. The cleavage was carried out following the general protocol and the crude was 
purified by reverse phase chromatography using semipreparative HPLC to give the major 
isomer of cyclic peptide 4 (8.80 mg, 3% overall yield).  
Major isomer 4: HPLC (gradient 1): 9.62 min (99% analytical purity). HRMS (ESI,+) m/z: 
calculated for C95H143N19O24S 1966.0274; found 1966.0339 (3.3 ppm). 
 
 Ac-RRRRRRRRR-PK-c[(CH2)3CH=CH(CH2)3]
3,7
[A
*
IQSA
*
]GISNLKNL-NH2 (5). 
The general elongation protocol was followed with 0.152 mmol of resin followed by 
acetylation and cleavage following the general protocol. After purification of the crude, 5 was 
isolated as a white lyophilized cotton-like solid (17.52 mg, 4% overall yield). Major isomer 5: 
HPLC: tR = 7.52 min (G2-100, 15 min), >99% purity (at 214 nm). MALDI-TOF-MS 
C124H231N53O26 2881.07.  
 
Ac-PKA
*
IQSA
*
GISNLKNL-NH2 (8). The general protocol for elongation was followed with 
0.038 mmol of resin. After acetylation, cleavage and purification, linear precursor 8 was 
obtained as a white solid (5.25 mg, 9% overall yield). 
HPLC (gradient 1): 10.11 min (>99% analytical purity). HRMS (ESI,+) m/z: calculated for 
C72H127N17O17 1501.9596; found 1501.9600 (0.31 ppm). 
 
Ac-PKIA
*
QSVA
*
ISNLKNL-NH2 (9). Following the general protocol for elongation with 0.038 
mmol of resin, and after acetylation, cleavage and purification, linear precursor 9 was obtained 
as a white solid (2.5 mg, 5% overall yield). 
HPLC (gradient 1): 6.08 min (97% analytical purity). HRMS (ESI,+) m/z: calculated for 
C73H129N17O17 1515.9752; found 1515.9732 (-1.29 ppm). 
 
2. Circular dichroism (CD) 
CD spectra were recorded in a Jasco J-815 spectropolarimeter (Tokyo, Japan) equipped with a 
Peltier PTC-423S system. Stocks of known peptide concentration (ca. 0.5-1 mM) were 
prepared by weighing the lyophilized material. The spectra was acquired in water/30%TFE 
solutions. TFE was chosen as cosolvent to increase the low water solubility of the peptides and 
because it is known that TFE stabilize pre-existing secondary structures in short lineal peptides 
[34,35]. Similar conditions were used previously to determine the CD spectra of related lactam-
bridged peptide analogues [29]. All measurements were carried out in triplicate at 25 °C and 
the cuvette path lengths were 0.1 cm for far UV region (250–195 nm). After subtracting 
appropriate reference spectra from the sample spectra, CD data were processed with the 
adaptative smoothing method of the Jasco SpectraAnalysis software. CD data are given in 
ellipticity units ([], deg.dmol.cm2.residue-1). The percentage of -helicity for 2a and 3a was 
calculated by the method described by Rohl and Baldwin [36] from the mean-residue ellipticity 
experimentally observed at 222 nm and the number of amino acids. 
 
 
3. Protease susceptibility assays 
Stock solutions of proteinase K were prepared in tris-buffered saline (TBS buffer) (50 μgmL-1) 
based on weight to volume). Stock solutions of the linear peptide 1 and hydrocarbon stapled 
peptides 2a and 3a (100 μM) were prepared using 10% DMSO in TBS buffer (pH 7.6, Aldrich). 
For the proteolysis reaction, the former peptide stock solutions (200 μL) were mixed with TBS 
(120 μL). Then, proteinase K stock solution (80 μL) was added (final concentration enzyme 10 
μgmL-1), the solution mixed, and finally allowed to proceed at room temperature with orbital 
shaking. Then, the enzymatic reaction was quenched (50 μL) at the desired time point (0, 5, 15, 
30, 60, 120, 240 and 360 min for linear peptide 1 and 0, 15, 30, 60, 120, 240 and 360, 480 min 
and 24 h or 0, 60, 120, 180, 240, 300, 360, 420 and 480 min for hydrocarbon-stapled analogues 
2a or 3a, respectively) by addition of 1% TFA in water/acetonitrile 1:1 (100 μL). 100 μL of the 
resulting quenched reaction was injected onto an HPLC and the amount of starting peptide 
present was quantified by mass integration of the peak at 214 nm. Duplicate or triplicate 
reactions were run for each time point reported and half-lives were determined by fitting time 
dependent peptide concentration to an exponential decay using GraphPad Prism. 
 
4. Li-TryR oxidoreductase activity 
Oxidoreductase activity was determined according to the method described by Hamilton et al. 
[40].
 Briefly, reactions were carried out at 26 ºC (250 μL) in HEPES buffer pH 8.0 (40 mM) 
containing EDTA (1 mM), NADPH (150 μM), NADP+ (30 μM), DTNB (25 μM), T[S]2 (1 
μM), glycerol (0.02%), DMSO (1.5%) and recombinant Li-TryR (7 nM). This standard reaction 
was modified by increasing DTNB, NADPH and NADP
+
 concentrations up to 100 μM, 
300 µM and 60 µM, respectively, when comparing the activity of the peptides against Li-TryR 
and H-GR. For IC50 determinations the enzyme was pre-incubated with the peptides 
(concentrations ranging from 75 μM to 0.29 μM) for 5 min prior to the addition of T[S]2 and 
NADPH. Enzyme activity was monitored by the increase in absorbance at 412 nm for 1 h at 26 
°C in a VERSAmax microplate reader (Molecular Devices, California, USA). All the assays 
were conducted in triplicate in at least three independent experiments. Data were analyzed 
using a non-linear regression model with the Grafit6 software (Erithacus, Horley, Surrey, UK). 
  
5. H-GR oxidoreductase activity 
Reactions were carried out at 26 ºC (250 μL) in HEPES buffer pH 8.0 (40 mM) containing 
EDTA 1 mM), NADPH (300 μM), NADP+ (60 μM), DTNB (100 μM), oxidized glutathione 
(GSSG, 1 μM), glycerol (0.02%), DMSO (1.5%) and recombinant H-GR (7 nM). The enzyme 
was pre-incubated with the peptides at 75 µM for 5 min prior to the addition of GSSG and 
NADPH. Enzyme activity was monitored by the increase in absorbance at 412 nm at 26 °C in a 
VERSAmax microplate reader (Molecular Devices, California, USA). All the assays were 
conducted in triplicate in three independent experiments. 
 
6. Dimer quantitation assay  
The stability of the Li-TryR dimeric form in the presence of stapled peptides 2 and 3 and linear 
precursors 8 and 9 was evaluated using the novel Enzyme-Linked ImmunoSorbent Assay 
(ELISA) recently developed in our laboratory [10]. Briefly a dual (HIS/FLAG) tagged Li-TryR 
(400 nM) was incubated in a dimerization buffer (200 µL 300 mM NaCl, 50 mM Tris pH 8.0) 
for 16 h at 37 °C with agitation and in a humid atmosphere in the presence of different peptide 
concentration (10 to 90 µM). Next the plates were washed ten times with TTBS (Tween 0.1%, 
2 mM Tris, 138 mM NaCl 138 pH 7.6) and incubated with diluted monoclonal α-HIS HRP 
conjugated antibody (200 µL, Abcam, Cambridge, UK) in BSA (5%) in TTBS for 1 h at room 
temperature. The plates were washed once again as previously described and 1,2-
phenylenediamine dihydrochloride (OPD) substrate (100 µL, Dako, Glostrup, Denmark) 
prepared according to manufacturer’s instructions was added. The enzymatic reaction was 
stopped after 10 min with H2SO4 (100 µL, 0.5 M) and the absorbances were measured at 490 
nm in a VERSAmax microplate reader (Molecular Devices, California, USA). All the assays 
were conducted in triplicate in at least three independent experiments. Data were analyzed 
using a non-linear regression model with the Grafit6 software (Erithacus, Horley, Surrey, UK).  
 
7. Cells and culture conditions.  
L. infantum axenic amastigotes were grown in M199 (Invitrogen, Leiden, The Netherlands) 
medium supplemented with 10% heat inactivated FCS, 1 g/L β-alanine, 100 mg/L L-
asparagine, 200 mg/L sacarose, 50 mg/L sodium pyruvate, 320 mg/L malic acid, 40 mg/L 
fumaric acid, 70 mg/L succinic acid, 200 mg/L α-ketoglutaric acid, 300 mg/L citric acid, 1.1 
g/L sodium bicarbonate, 5 g/L MES, 0.4 mg/L hemin, 10 mg/L gentamicine pH 5.4 at 37 ºC. 
THP-1 cells were grown in RPMI-1640 medium (Gibco, Leiden, The Netherlands) 
supplemented with 10% heat inactivated FCS, antibiotics, 1 mM HEPES, 2 mM glutamine and 
1 mM sodium pyruvate, pH 7.2 at 37 ºC and 5% CO2. 
L. infantum promastigotes (MCAN/ES/ 89/IPZ229/1/89) were grown in RPMI-1640 medium 
(Sigma–Aldrich, St. Louis, MO, USA) supplemented with 10% heat-inactivated fetal calf 
serum (FCS), antibiotics, and 25 mm HEPES (pH 7.2) at 26 
o
C. 
 
8. Leishmanicidal activity and cytotoxicity assays.  
Drug treatment of amastigotes was performed during the logarithmic growth phase at a 
concentration of 1×10
6
 parasites/mL at 37 ºC for 24 h. Drug treatment of promastigotes was 
performed during the logarithmic growth phase at a concentration of 2×10
6
 parasites/mL at 26 
ºC for 24 h. Drug treatment of THP-1 cells was performed during the logarithmic growth phase 
at a concentration of 4×10
5
 cells/mL at 37 ºC and 5% CO2 for 24 h. LC50 was evaluated by flow 
cytometry by the propidium iodide (PI) exclusion method [41]. After selection of the parasite 
population based on their forward scatter (FSC) and side scatter (SSC) values, live and dead 
parasite cells were identified by their permeability to PI. This is a conservative procedure that 
may underestimate EC50 values as parasites that become fragmented as a result of cell death are 
excluded from the analysis. To minimize the presence of fragmented parasites drug treatment 
never exceeded 24 hours. 
 
Appendix A. Supplementary data 
HPLC, HRMS or MALDI-TOF-MS of linear precursors and all-hydrocarbon stapled 
analogues, 
1
H- and 
13
C-NMR data and NMR spectra of stapled peptides 2a,b and 3a, 
proteolysis stability data  and TryR dimerization assay data are included.  
 
Supplementary data related to this article can be found at http:// 
dx.doi.org/10.1016/j.ejmech.2018.xx.xxx. 
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